Thus, CD47 seems to be a promising therapeutic target only in specific forms of B-cell lymphoma, such as DLBCL, in which it also correlated with poor prognosis, as detailed in our previous work [43]. This evidence concerns the gene CD47 and B-cell non-Hodgkin lymphoma.